Oxana Komina

Whether to target single or multiple CDKs for therapy? That is the question

Józefa Węsierska‐Gądek, Margarita Maurer‐Granofszky, Nora Zulehner et al. · Journal of Cellular Physiology · 2010 · 49 citations

Chemoprevention Strategy, Pharmacotherapy, Cell Cycle +20

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen‐induced phosphorylation of ER‐α in human ER‐positive breast cancer cells

Józefa Węsierska‐Gądek, David Gritsch, Nora Zulehner et al. · Journal of Cellular Biochemistry · 2010 · 46 citations

Breast Oncology, Cell Death, Cell Cycle +23

Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway

Zsuzsanna Bagó-Horváth, Wolfgang Sieghart, Michael Grusch et al. · Neuroendocrinology · 2012 · 31 citations

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells

Józefa Węsierska‐Gądek, Nora Zulehner, Franziska Ferk et al. · Biochemical Pharmacology · 2012 · 30 citations · Full text

Different Brca1, Breast Oncology, Parp Inhibition +14

Characterization of Autoantibodies against Components of the Nuclear Pore Complexes

Józefa Węsierska‐Gądek, ANNA KLIMA, Oxana Komina et al. · Annals of the New York Academy of Sciences · 2007 · 26 citations

Immunocytochemical Technique, Immunology, Glycobiology +18